Overview
- Boston Scientific, which reported results Wednesday, posted $5.20 billion in revenue and adjusted earnings of 80 cents per share that landed at or just above forecasts.
- The company lowered its 2026 adjusted earnings range to $3.34 to $3.41 per share and trimmed its full-year organic sales growth view to 6.5% to 8%.
- Management guided for the June quarter to 82 to 84 cents in adjusted earnings and $5.34 billion to $5.44 billion in sales, which trails typical Wall Street estimates.
- Following a 52-week low of $60.54 on Tuesday, the shares were up about 9% in Wednesday trading, according to Benzinga.
- Analysts cut price targets yet kept Buy or Outperform ratings, and they are watching hospital purchasing data in electrophysiology and recent Watchman implant headlines for signs of demand.